CJC-1295 without DAC (Mod GRF 1-29) (10 mg Vial) Dosage Protocol
CJC-1295 without DAC (also called Modified GRF 1-29) is a 30-amino-acid synthetic GHRH analog with a half-life of ~30 minutes. It produces a discrete GH pulse rather than sustained elevation.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = 3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg | 4.5 units (0.045 mL) |
| Weeks 5–6 | 200 mcg | 6 units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg | 7.5–9 units (0.075–0.09 mL) |
Frequency: Inject once daily subcutaneously, typically at bedtime to align with natural nocturnal GH pulsatility. For ≤10‑unit (≤0.10 mL) administrations (Weeks 1–4), consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Calculated from the schedule above for a 10 mg vial reconstituted with 3 mL (one injection per day, two swabs per injection).
| Item | 8 weeks | 12 weeks | 16 weeks |
|---|---|---|---|
| Peptide vials (10 mg each) | 2 vials (10.5 mg total) | 2 vials (18.9 mg total) | 3 vials (27.3 mg total) |
| Insulin syringes (U-100) | 56 syringes | 84 syringes | 112 syringes |
| Bacteriostatic water (10 mL bottles) | 6 mL → 1 × 10 mL bottle | 6 mL → 1 × 10 mL bottle | 9 mL → 1 × 10 mL bottle |
| Alcohol swabs | 112 swabs → 2 × 100-count boxes | 168 swabs → 2 × 100-count boxes | 224 swabs → 3 × 100-count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
CJC-1295 without DAC contains the same four stabilizing amino acid substitutions as the DAC version (D-Ala2, Gln8, Ala15, Leu27) but lacks the albumin-binding linker. The result is a stable, short-acting GHRH analog producing a discrete GH pulse over ~30 minutes.
Common practice combines CJC-1295 with ipamorelin (a GHRP) — the GHRH stimulates GH release while the GHRP synergistically amplifies it, mimicking the body’s natural feedback patterns.
Potential Benefits & Side Effects
Potential Benefits
- Discrete pulsatile GH release mimicking physiological pattern.
- Often combined with ipamorelin for synergistic GH pulses.
- Improvements in sleep quality reported.
- Body composition and recovery effects via sustained protocols.
Side Effect Profile
- Injection-site reactions.
- Mild head flushing or fullness post-dose.
- Transient water retention.
- Hunger increase (some users).
Lifestyle Factors
- Avoid eating for 30+ min after injection — meals blunt GH release.
- Pre-bed dosing aligns with natural GH pulse during slow-wave sleep.
- Resistance training amplifies anabolic effects.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm.
- Rotate sites with each dose.
- 90° angle with short insulin needle.